04.12.2018 • NewsDede WillamsMerckProcter & Gamble

Merck KGaA Completes Consumer Health Sale

Merck KGaA Completes Consumer Health Sale (c) P&G
Merck KGaA Completes Consumer Health Sale (c) P&G

German pharmaceuticals, chemicals and laboratory products group Merck completed the sale of its Consumer Health business to US consumer products group Procter & Gamble (P&G) on Dec. 1. Belén Garijo, CEO Healthcare, called the transaction – which she said was completed within an ambitious timeframe – “an important milestone for both Merck and Consumer Health.”

The asset transfer for € 3.4 billion in cash, which was executed through the sale of Merck’s shares in a number of legal entities as well as various asset sales, follows consultations with employee representatives, approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. The European Commission gave its green light at the end of August.

Some 3,300 employees, mainly from consumer health, have transferred to P&G. As part of the transaction, Merck and P&G have agreed to a number of manufacturing, supply, and service agreements.

The German group’s consumer health business operates in 44 countries and manufactures more than 900 products. It has two consumer health-managed production sites at Spittal, Austria, and Goa, India.

With the purchase, P&G will be able to add Merck’s vitamin and food supplements, such as Seven Seas, to its portfolio and also boost its presence in Latin America and Asia. The US group manufactures a range of over-the-counter medicines such as Vicks cough and cold products, along with well-known brands such as Pampers diapers and Gillette razors.

After deducting taxes and transaction-related effects, Merck plans to use the net cash proceeds of about € 2.7 billion primarily to further reduce its financial debt. With the sale, the company has now hit its 2018 leverage target of a net debt to EBITDA pre-ratio of less than 2, said chief financial officer Marcus Kuhnert, who added that shedding Consumer Health will increase Merck’s flexibility to focus on innovation-driven businesses within three business sectors.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.